Of all the misconceptions surrounding testosterone replacement therapy, the fear of prostate cancer is perhaps the most persistent — and the most consequential. It has caused generations of men to suffer from testosterone deficiency unnecessarily, denied effective treatment by clinicians who were taught that testosterone “feeds” prostate cancer. The reality, as revealed by decades of research, is far more nuanced — and far more reassuring.
The Origins of the Fear: The Huggins and Hodges Hypothesis
The concern originated from a 1941 paper by Charles Huggins and Clarence Hodges, who demonstrated that surgical castration (and thus testosterone elimination) caused regression of metastatic prostate cancer — a finding that earned Huggins the 1966 Nobel Prize. The logical inverse — that giving testosterone would accelerate prostate cancer — became medical dogma, despite never being rigorously tested in the original research.
Want to talk it through with our team?
Book a free 15-minute video consult. Start for $247 — includes your first doctor visit. No membership.
What the Modern Evidence Actually Shows
The “saturation model,” developed by Dr. Abraham Morgentaler at Harvard Medical School, provides a more accurate framework. Prostate cells contain a finite number of androgen receptors that can be fully saturated at relatively low testosterone concentrations. Above this saturation threshold, additional testosterone does not further stimulate prostate cell growth. This explains why men with low testosterone do not have less prostate cancer, and why raising testosterone from deficient to normal levels does not increase prostate cancer risk.
Multiple large epidemiological studies and meta-analyses have confirmed: low testosterone is actually associated with higher Gleason grade prostate cancers and more aggressive disease at diagnosis. TRT in men with carefully monitored, treated, and stable prostate cancer has been shown in multiple studies to be feasible without increasing recurrence risk. The largest prospective registries of TRT patients do not show elevated prostate cancer incidence compared to age-matched controls.
Appropriate Monitoring on TRT
None of this means TRT should be initiated without prostate monitoring. At Multigen Wellness, all male patients receive baseline PSA (prostate-specific antigen) testing and digital rectal examination prior to TRT, with PSA monitoring every 6–12 months thereafter. Men with a history of prostate cancer require a more individualized risk-benefit discussion with their oncologist. But for the vast majority of men with testosterone deficiency and no prostate pathology, fear of prostate cancer should not be a barrier to treatment. Call +1 (800) 259-0015 to discuss TRT safely and properly monitored.
Recommended Reading
Want to go deeper on hormone health? Two books from our team break it down in plain language:
How it works
From your first call to medication at your door.
- AFree 15-minute video consult. We go over your goals, answer your questions, and confirm we can treat you in your state.
- BStart for $247, which includes your first doctor visit.
- CLab work: free with insurance at Quest or any other lab. Book your Quest visit in your patient portal, or take our lab order form to any lab that takes your insurance.
- DDoctor visit: once results are back, meet by video with a dedicated hormone therapy specialist (PAs, NPs and doctors on staff) to review labs and plan medication or therapy.
- EMedication shipped to your door. We bill you for the medication and ship it to your house. See medication prices
What it costs
- No monthly fee, no membership, no commitment.
- $97 per visit, only when needed.
- Prescriptions need lab work and a video visit at least every 90 days.
- Most new patients are seen every 30 days at first.